Nasal spray lowers Covid viral load by 94 percent in 24 hours: Lancet study


PTI, Jul 16, 2022, 10:13 AM IST

Credit: iStock Photo

A nasal spray administered in high-risk adult COVID-19 patients in India reduced viral load by 94 percent within 24 hours and 99 percent in 48 hours, according to the results of a phase 3 trial of the drug published in The Lancet Regional Health Southeast Asia journal.

The study on Nitric Oxide Nasal Spray (NONS) was conducted by Mumbai-based pharmaceutical company Glenmark on 306 vaccinated and unvaccinated adults with symptomatic mild COVID-19 across 20 clinical sites in India.

The trial evaluated a seven-day treatment of NONS plus standard of care versus placebo nasal spray and standard care in patients with symptomatic COVID-19. NONS was self-administered six times daily as two sprays per nostril for seven days.

The study was conducted during the Delta and Omicron surges. The research found that high-risk patients who received NONS had a significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.

Viral load was reduced by 93.7 percent within 24 hours and by 99 percent within 48 hours of treatment with NONS. Similar results were observed in vaccinated and unvaccinated populations, the authors said.

”The robust double-blind trial demonstrated significant efficacy and remarkable safety of NONS,” Monika Tandon, Senior VP & Head – Clinical Development, Glenmark, and one of the authors of the study said.

”This therapy has the potential to make a crucial contribution to COVID-19 management, with its ease of use in the current highly transmissible phase of pandemic,” Tandon said in a statement.

NONS was launched in India under the brand name FabiSpray in February after it received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) as part of the accelerated approval process.

Nitric Oxide blocks entry into the nasal passage kills the virus, and stops its replication, which is why the viral load is reduced so rapidly with NONS, the statement said.

The median time to viral cure was three days in the NONS group and seven days in the placebo group after the start of the treatment, it said.

The proportion of immediate contacts having a positive COVID-19 test or becoming symptomatic, remained nearly the same in the NONS group while it numerically increased in the placebo group over the treatment, the authors added.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Actress Kasthuri released from jail, says ‘I thank those who made me raging storm’

Kidnapped for ransom in 1998, 26/11 survivor Gautam Adani faces biggest trial

100 engineering colleges in Karnataka to be ‘adopted’ by corporates by next year: IT Minister Kharge

Siddaramaiah defends BPL ration card cancellation, says only ineligible beneficiaries affected

China announces new policy measures to protect its exports from Trump’s new tariff threat

Renovated Medical Oncology OPD and Chemotherapy Day Care Centre inaugurated at Kasturba Hospital, Manipal

Karnataka Health Minister justifies revision of user fees in state-run hospitals

Related Articles More

World COPD Day: Know your lung function

As Delhi chokes with dangerous pollution levels, doctors warn of health risks for all

World Diabetes Day 2024: Kasturba Hospital Manipal Hosts Zumba Session at Malpe Beach to Raise Diabetes Awareness

World Diabetes Day: An overview of types of diabetes

World Diabetes Day: One-fourth of people living with diabetes in 2022 are in India, Lancet study estimates

MUST WATCH

Christmas Cake Fruit Mixing

DK Shivakumar

Rose Cultivation

Geethotsava

Naxal Operation


Latest Additions

Siddaramaiah says confident of winning all three bypolls in Karnataka

Hop on! IT Minister Priyank Kharge checks out Uber Shuttle at Bengaluru Tech Summit

Actress Kasthuri released from jail, says ‘I thank those who made me raging storm’

Kidnapped for ransom in 1998, 26/11 survivor Gautam Adani faces biggest trial

AIMPLB to hold its annual general sessions in Bengaluru from November 23

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.